Funding for this research was provided by:
Vertex Pharmaceuticals (Cystic Fibrosis Research Innovation Award)
National Institute of Allergy and Infectious Diseases (U01 AI124316-01)
Received: 14 August 2018
Accepted: 29 January 2019
First Online: 13 February 2019
Ethics approval and consent to participate
: This study was approved by the UC San Diego institutional review board under protocol for human subject research (#160078). All subjects provided informed consent to participate.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.